Next Article in Journal
Effect of Acceptor and Donor Substituents in the ortho, meta, and para Positions in the Nitrobenzene Molecule on the Reaction of Interaction with Ethylene
Previous Article in Journal
Open Bottom Production in Au Au Collisions at √sNN = 200 GeV with the STAR Experiment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Extended Abstract

Cytoprotective and Antioxidants in Peroxisomal Neurodegenerative Diseases †

1
NutRedOx Network (COST Action CA16112), 1050 Brussels, Belgium
2
BioPeroxIL laboratory, Université de Bourgogne-Franche Comté, 6, Boulevard Gabriel, 21000 Dijon, France
3
Organic Chemistry Division, Department of Chemistry, Faculty of Science, Mansoura University, El-Gomhorya Street, 35516 Mansoura, Egypt
4
Institute of Organic Chemistry and Chemical Biology, Goethe-University Frankfurt, Max-von-Laue-Str. 7, 60438 Frankfurt/Main, Germany
5
Laboratoire de Biochimie et Neurosciences, Faculté des Sciences et Techniques, Université Hassan I, BP577, 26000 Settat, Morocco
6
Botany Department, Faculty of Science, Mansoura University, 35516 Mansoura, Egypt
7
Institut de Chimie Moléculaire de l’Université de Bourgogne-Franche Comté, UMR6302, CNRS, Université Bourgogne Franche Comté, F-21000 Dijon, France
8
Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B2 1, D-66123 Saarbuecken, Germany
*
Author to whom correspondence should be addressed.
Presented at the Natural Products and the Hallmarks of Chronic Diseases—COST Action 16112, Luxemburg, 25–27 March 2019.
Proceedings 2019, 11(1), 33; https://doi.org/10.3390/proceedings2019011033
Published: 28 April 2019
(This article belongs to the Proceedings of CA16112 - Luxemburg 2019)
Several of the peroxisomal neurodegenerative disorders are the consequence of a specific deficiency of an enzyme or a transporter involved in peroxisomal beta-oxidation of very long chain fatty acids [1,2]. One of the hallmarks in these peroxisomal rare neurodegenerative diseases and in other common demyelinating disorders is the accompanying oxidative damage and neuroinflammation [3]. Compelling data indicates that oxidative stress can activate microglia leading to the overproduction of pro-inflammatory molecules [4,5]. Thus, targeting oxidative stress to limit neuroinflammation may open a new pharmacological therapy window for these still incurable devastating peroxisomal diseases. Here, we present different natural (resveratrol) [6] and synthetic (organoselenides) [7] antioxidant compounds for their capacity of scavenging oxidative stress and in the perspective therapeutic use against oxidative damage in peroxisomal disorders.

Acknowledgments

This abstract and the oral presentation are based upon work from COST Action NutRedOx-CA16112 supported by COST (European Cooperation in Science and Technology). The “Ministère des Affaires Etrangères: the Embassy of France in Egypt-Institut Français en Egypte” and the “Science and Technology Development Fund” by according to a postdoctoral fellowships to S. Shaaban and to A. El-shobaky. This work was also supported by the PHC Volubilis/Toubkal program of the Comité Mixte Inter-universitaire Franco-Marocain (CMIFM, MA/14/310 and TBK 19/92—CAMPUS: 41501RJ).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Wanders, R.J. Metabolic functions of peroxisomes in health and disease. Biochimie 2014, 98, 36–44. [Google Scholar] [CrossRef] [PubMed]
  2. Trompier, D.; Vejux, A.; Zarrouk, A.; Gondcaille, C.; Geillon, F.; Nury, T.; Savary, S.; Lizard, G. Brain peroxisomes. Biochimie 2014, 98, 102–110. [Google Scholar] [CrossRef] [PubMed]
  3. Singh, I.; Pujol, A. Pathomechanisms underlying X-adrenoleukodystrophy: A three-hit hypothesis. Brain Pathol. 2010, 20, 838–844. [Google Scholar] [CrossRef] [PubMed]
  4. Raas, Q.; Saih, F.-E.; Gondcaille, C.; Trompier, D.; Hamon, Y.; Leoni, V.; Caccia, C.; Nasser, B.; Jadot, M.; Ménétrier, F.; et al. A microglial cell model for acyl-CoA oxidase 1 deficiency. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2019, 1864, 567–576. [Google Scholar] [CrossRef] [PubMed]
  5. Raas, Q.; Gondcaille, C.; Hamon, Y.; Leoni, V.; Caccia, C.; Ménétrier, F.; Lizard, G.; Trompier, D.; Savary, S. CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: Novel microglial models for X-linked Adrenoleukodystrophy. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2019, 1864, 704–714. [Google Scholar] [CrossRef] [PubMed]
  6. Latruffe, N.; Lançon, A.; Frazzi, R.; Aires, V.; Delmas, D.; Michaille, J.-J.; Djouadi, F.; Bastin, J.; Cherkaoui-Malki, M. Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation. Ann. N. Y. Acad. Sci. 2015, 1348, 97–106. [Google Scholar] [CrossRef] [PubMed]
  7. Shaaban, S.; Vervandier-Fasseur, D.; Andreoletti, P.; Zarrouk, A.; Richard, P.; Negm, A.; Manolikakes, G.; Jacob, C.; Cherkaoui-Malki, M. Cytoprotective and antioxidant properties of organic selenides for the myelin-forming cells, oligodendrocytes. Bioorg. Chem. 2018, 80, 43–56. [Google Scholar] [CrossRef] [PubMed]

Share and Cite

MDPI and ACS Style

Cherkaoui-Malki, M.; Shaaban, S.; Tahri-Joutey, M.; Elshobaky, A.; Saih, F.-E.; Vervandier-Fasseur, D.; Jacob, C.; Nasser, B.; Latruffe, N.; Andreoletti, P. Cytoprotective and Antioxidants in Peroxisomal Neurodegenerative Diseases. Proceedings 2019, 11, 33. https://doi.org/10.3390/proceedings2019011033

AMA Style

Cherkaoui-Malki M, Shaaban S, Tahri-Joutey M, Elshobaky A, Saih F-E, Vervandier-Fasseur D, Jacob C, Nasser B, Latruffe N, Andreoletti P. Cytoprotective and Antioxidants in Peroxisomal Neurodegenerative Diseases. Proceedings. 2019; 11(1):33. https://doi.org/10.3390/proceedings2019011033

Chicago/Turabian Style

Cherkaoui-Malki, Mustapha, Saad Shaaban, Mounia Tahri-Joutey, Ahmed Elshobaky, Fatima-Ezzahra Saih, Dominique Vervandier-Fasseur, Claus Jacob, Boubker Nasser, Norbert Latruffe, and Pierre Andreoletti. 2019. "Cytoprotective and Antioxidants in Peroxisomal Neurodegenerative Diseases" Proceedings 11, no. 1: 33. https://doi.org/10.3390/proceedings2019011033

Article Metrics

Back to TopTop